移植后糖尿病危险因素研究进展

董骏峰; 薛强; 滕飞; 赵渊宇; 殷浩

doi:10.3969/j.issn.1674-7445.2023154

移植后糖尿病危险因素研究进展

doi: 10.3969/j.issn.1674-7445.2023154

董骏峰^1,,
薛强²,
滕飞¹,
赵渊宇¹,
殷浩^1, ,

1.
200003　上海，海军军医大学第二附属医院（上海长征医院）器官移植科
2.
海军军医大学第三附属医院（东方肝胆外科医院）神经外科

基金项目: 国家自然科学基金面上项目（82070798）；上海市科学技术委员会生物医药创新项目（21S11905200）；上海申康医院发展中心新兴前沿技术联合攻关项目（SHDC12021116）；上海申康医院发展中心研究型医师创新转化能力培训项目（SHDC2022CRD030）；上海长征医院转化医学孵育基金；上海长征医院科普人才扶持计划（CZQNKP-TYYX-QZ-2022-05）

详细信息

作者简介:

通讯作者:
殷浩（ORCID 0000-0001-5674-8681），主任医师，全军器官移植研究所所长，国家重点学科/国家临床重点专科学科带头人，研究方向为肝胆胰腺外科及器官移植，Email：roytina0241032@hotmail.com

中图分类号: R617, R587.1
计量
- 文章访问数: 227
- HTML全文浏览量: 169
- PDF下载量: 34
- 被引次数: 0
出版历程
- 收稿日期: 2023-08-02
- 网络出版日期: 2023-11-29
- 刊出日期: 2024-01-11

Research progress in risk factors of post-transplantation diabetes mellitus

1.
Department of Organ Transplantation, the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China

More Information

Corresponding author: Yin Hao, Email: roytina0241032@hotmail.com

摘要

摘要: 实体器官移植极大地延长了终末期疾病患者的生存时间，但器官移植受者术后需要长期服用免疫抑制药，会导致移植后糖尿病（PTDM）的发生风险增加，从而使感染、心血管疾病和死亡的风险升高。近年来，随着PTDM诊断标准的不断完善，临床医师对其认识越来越深入，与2型糖尿病相比，PTDM在病理生理特征和临床进展上存在着明显差异，需采用不同的治疗策略。及早识别器官移植受者的危险因素，早期诊断和干预对于改善受者的生活质量，延长移植物的存活时间以及降低受者病死率具有重要意义。因此，本文就PTDM的诊断、发生情况及危险因素做一综述，以期为临床医师早期识别并干预PTDM提供参考。
- 器官移植 /
- 移植后糖尿病 /
- 钙调磷酸酶抑制剂 /
- 哺乳动物雷帕霉素靶蛋白抑制剂 /
- 糖皮质激素 /
- 巨细胞病毒 /
- 排斥反应 /
- 单核苷酸多态性
Abstract: Solid organ transplantation has significantly prolonged the survival of patients with end-stage diseases. However, long-term use of immunosuppressants will increase the risk of post-transplantation diabetes mellitus (PTDM) in the recipients, thereby elevating the risk of infection, cardiovascular disease and death. In recent years, with persistent improvement of diagnostic criteria of PTDM, clinicians have deepened the understanding of this disease. Compared with type 2 diabetes mellitus, PTDM significantly differs in pathophysiological characteristics and clinical progression. Hence, different treatment strategies should be adopted. Early identification of risk factors of organ transplant recipients, early diagnosis and intervention are of significance for improving the quality of life of recipients, prolonging the survival of grafts and reducing the fatality of recipients. Therefore, the diagnosis, incidence and risk factors of PTDM were reviewed in this article, aiming to provide reference for clinicians to deliver prompt diagnosis and intervention for PTDM.
- Organ transplantation /
- Post-transplantation diabetes mellitus /
- Calcineurin inhibitor /
- Mammalian target of rapamycin inhibitor /
- Glucocorticoid /
- Cytomegalovirus /
- Rejection /
- Single nucleotide polymorphism

HTML全文

下载: 全尺寸图片幻灯片

参考文献(39)

[1]	DE LA FUENTE-MANCERA JC, FORADO-BENTAR I, FARRERO M. Management of long-term cardiovascular risk factors post organ transplant[J]. Curr Opin Organ Transplant, 2022, 27(1): 29-35. DOI: 10.1097/MOT.0000000000000950.
[2]	SHARIF A. Prevention of post-transplantation diabetes: small steps, big opportunities[J]. J Am Soc Nephrol, 2021, 32(8): 1833-1834. DOI: 10.1681/ASN.2021060777.
[3]	WANG Q, WU J, WANG X, et al. Risk factors of new-onset diabetes after renal transplantation and prognostic analysis[J]. Altern Ther Health Med, 2023, 29(2): 230-235.
[4]	中国康复医学会器官移植康复专业委员会. 成人实体器官移植后糖尿病管理专家共识[J]. 器官移植, 2023, 14(5): 623-642. DOI: 10.3969/j.issn.1674-7445.2023110. Organ Transplantation and Rehabilitation Committee of Chinese Medical Association of Rehabilitation. Expert consensus on diabetes mellitus after solid organ transplantation in adults[J]. Organ Transplant, 2023, 14(5): 623-642. DOI: 10.3969/j.issn.1674-7445.2023110.
[5]	HE J, YANG M, QUAN X, et al. Microbial and metabolic features in renal transplant recipients with post-transplantation diabetes mellitus[J]. Int J Urol, 2023, 30(6): 504-513. DOI: 10.1111/iju.15158.
[6]	陈荣鑫, 赖兴强, 张磊, 等. 肾移植受者发生移植后糖尿病的危险因素分析及预测模型的构建[J]. 器官移植, 2021, 12(3): 329-335. DOI: 10.3969/j.issn.1674-7445.2021.03.012. CHEN RX, LAI XQ, ZHANG L, et al. Analysis of risk factors and establishment of prediction model for post transplantation diabetes mellitus in renal transplant recipients[J]. Organ Transplant, 2021, 12(3): 329-335. DOI: 10.3969/j.issn.1674-7445.2021.03.012.
[7]	WANG L, HUANG J, LI Y, et al. Postoperative fasting plasma glucose and family history diabetes mellitus can predict post-transplantation diabetes mellitus in kidney transplant recipients[J]. Endocrine, 2023, 81(1): 58-66. DOI: 10.1007/s12020-023-03374-y.
[8]	SHARIF A, HECKING M, DE VRIES AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9): 1992-2000. DOI: 10.1111/ajt.12850.
[9]	LIN Y, MOK M, HARRISON J, et al. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: a systematic review[J]. Transplant Rev (Orlando), 2023, 37(1): 100729. DOI: 10.1016/j.trre.2022.100729.
[10]	HARREITER J, RODEN M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023)[J]. Wien Klin Wochenschr, 2023, 135(Suppl 1): 7-17. DOI: 10.1007/s00508-022-02122-y.
[11]	HECKING M, SHARIF A, ELLER K, et al. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics[J]. Transpl Int, 2021, 34(1): 27-48. DOI: 10.1111/tri.13783.
[12]	CHAITOU AR, VALMIKI S, VALMIKI M, et al. New-onset diabetes mellitus (NODM) after liver transplantation (lt): the ultimate non-diabetogenic immunosuppressive therapy[J]. Cureus, 2022, 14(3): e23635. DOI: 10.7759/cureus.23635.
[13]	JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.
[14]	PAUCHET A, SCHWOTZER N, LAMINE F, et al. Post-transplantation diabetes in kidney transplant: from the diabetologist point of view[J]. Rev Med Suisse, 2020, 16(697): 1200-1205.
[15]	SHIVASWAMY V, BOERNER B, LARSEN J. Post-Transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61. DOI: 10.1210/er.2015-1084.
[16]	ZHANG Z, SUN J, GUO M, et al. Progress of new-onset diabetes after liver and kidney transplantation[J]. Front Endocrinol (Lausanne), 2023, 14: 1091843. DOI: 10.3389/fendo.2023.1091843.
[17]	REID L, BAXTER F, FORBES S. Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes[J]. Diabet Med, 2021, 38(7): e14570. DOI: 10.1111/dme.14570.
[18]	KIM NG, SHARMA A, SAAB S. Cardiovascular and metabolic disease in the liver transplant recipient[J]. Best Pract Res Clin Gastroenterol, 2020, 46/47: 101683. DOI: 10.1016/j.bpg.2020.101683.
[19]	DE VRIES DK, LINDEMAN JH, RINGERS J, et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation[J]. Am J Transplant, 2011, 11(5): 1064-1070. DOI: 10.1111/j.1600-6143.2011.03466.x.
[20]	NAESENS M, LI L, YING L, et al. Expression of complement components differs between kidney allografts from living and deceased donors[J]. J Am Soc Nephrol, 2009, 20(8): 1839-1851. DOI: 10.1681/ASN.2008111145.
[21]	ABDELAZIZ TS, ALI AY, FATTHY M. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and meta-analysis[J]. Curr Diabetes Rev, 2020, 16(6): 580-585. DOI: 10.2174/1573399815666190321144310.
[22]	中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14,28. DOI: 10.3969/j.issn.1674-7445.2021.01.002. Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14,28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
[23]	张岑, 王文妍, 文力. 类固醇相关糖尿病风险防范及诊治[J]. 临床药物治疗杂志, 2023, 21(8): 18-21. DOI: 10.3969/j.issn.1672-3384.2023.08.004. ZHANG C, WANG WY, WEN L. Risk prevention and treatment of steroid-induced diabetes mellitus[J]. Clin Med J, 2023, 21(8): 18-21. DOI: 10.3969/j.issn.1672-3384.2023.08.004.
[24]	WOODLE ES, FIRST MR, PIRSCH J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy[J]. Ann Surg, 2008, 248(4): 564-577. DOI: 10.1097/SLA.0b013e318187d1da.
[25]	WEBSTER AC, WOODROFFE RC, TAYLOR RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data[J]. BMJ, 2005, 331(7520): 810. DOI: 10.1136/bmj.38569.471007.AE.
[26]	NOGUEIRAS-ÁLVAREZ R, MORA-CUESTA VM, CIFRIÁN-MARTÍNEZ JM, et al. Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain[J]. Sci Rep, 2022, 12(1): 21207. DOI: 10.1038/s41598-022-25445-2.
[27]	WANG Z, JIANG Z, LU R, et al. Formulation strategies to provide oxygen-release to contrast local hypoxia for transplanted islets[J]. Eur J Pharm Biopharm, 2023, 187: 130-140. DOI: 10.1016/j.ejpb.2023.04.015.
[28]	VAN LAECKE S, VAN BIESEN W, VERBEKE F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation[J]. Am J Transplant, 2009, 9(9): 2140-2149. DOI: 10.1111/j.1600-6143.2009.02752.x.
[29]	LOMBARDI Y, FRANÇOIS H. Belatacept in kidney transplantation: what are the true benefits? a systematic review[J]. Front Med (Lausanne), 2022, 9: 942665. DOI: 10.3389/fmed.2022.942665.
[30]	ARAKI M, FLECHNER SM, ISMAIL HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs[J]. Transplantation, 2006, 81(3): 335-341. DOI: 10.1097/01.tp.0000195770.31960.18.
[31]	CAMAYA I, DONNELLY S, O'BRIEN B. Targeting the PI3K/Akt signaling pathway in pancreatic β-cells to enhance their survival and function: an emerging therapeutic strategy for type 1 diabetes[J]. J Diabetes, 2022, 14(4): 247-260. DOI: 10.1111/1753-0407.13252.
[32]	OTHMAN N, GHEITH O, AL-OTAIBI T, et al. Effect of structured diabetes education on diabetic angiopathies among kidney transplant recipients with posttransplant diabetes: kuwait experience[J]. Exp Clin Transplant, 2022, 20(Suppl 1): 46-54. DOI: 10.6002/ect.MESOT2021.O19.
[33]	DELOS SANTOS RB, HAGOPIAN JC, CHEN L, et al. Sitagliptin versus placebo to reduce the incidence and severity of posttransplant diabetes mellitus after kidney transplantation-a single-center, randomized, double-blind controlled trial[J]. Transplantation, 2023, 107(5): 1180-1187. DOI: 10.1097/TP.0000000000004373.
[34]	KATHIRVEL M, MALLICK S, SETHI P, et al. Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT)[J]. HPB (Oxford), 2021, 23(5): 666-674. DOI: 10.1016/j.hpb.2020.09.012.
[35]	尚梦月, 陈永忠, 保洁, 等. 慢性乙型肝炎合并代谢相关脂肪性肝病的临床及病理特点分析[J]. 中华肝脏病杂志, 2023, 31(2): 126-132. DOI: 10.3760/cma.j.cn501113- 20220701-00362. SHANG MY, CHEN YZ, BAO J, et al. Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease[J]. Chin J Hepatol, 2023, 31(2): 126-132. DOI: 10.3760/cma.j.cn501113-20220701-00362.
[36]	张绍丽, 曹毛毛, 杨帆, 等. 1990—2019年中国人群肝癌各病因疾病负担变化趋势分析[J]. 中华消化外科杂志, 2023, 22(1): 122-130. DOI: 10.3760/cma.j.cn115610- 20221112-00687. ZHANG SL, CAO MM, YANG F, et al. Analysis of the change trend of etiological burden of disease of liver cancer in the Chinese population from 1990 to 2019[J]. Chin J Dig Surg, 2023, 22(1): 122-130. DOI: 10.3760/cma.j.cn115610-20221112-00687.
[37]	PISANO G, FRACANZANI AL, CACCAMO L, et al. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study[J]. World J Gastroenterol, 2016, 22(40): 8869-8882. DOI: 10.3748/wjg.v22.i40.8869.
[38]	PATIL DT, YERIAN LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation[J]. Liver Transpl, 2012, 18(10): 1147-1153. DOI: 10.1002/lt.23499.
[39]	ANDRADE AR, BITTENCOURT PL, CODES L, et al. New onset diabetes and non-alcoholic fatty liver disease after liver transplantation[J]. Ann Hepatol, 2017, 16(6): 932-940. DOI: 10.5604/01.3001.0010.5285.